Literature DB >> 7695331

Utilization of time-kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against Helicobacter pylori in stationary and logarithmic growth phases.

P E Coudron1, C W Stratton.   

Abstract

Assessment of in vitro susceptibility testing of Helicobacter pylori is difficult because of the fastidious, slowly growing nature of this microorganism. The high rate of relapse observed clinically and a possible subpopulation of cells that are not actively replicating suggest the potential need for bactericidal therapy in order to eradicate H. pylori. We used modified time-kill kinetic methodology in order to evaluate the bactericidal activities of ampicillin and bismuth, alone and in combination, against three strains of H. pylori in both a stationary (slow) growth phase and a logarithmic (rapid) growth phase. We found that ampicillin produced a decrease in CFU per milliliter (2 to 4 log10 units) for three strains of H. pylori when tested in logarithmic growth phases but was less inhibitory (< 1-log10-unit decrease in CFU per milliliter) when tested in a stationary growth phase. In contrast, bismuth, when tested in a logarithmic growth phase, produced little inhibitory effect, as the CFU for all strains tested increased above the inoculum. However, when tested in a stationary growth phase, bismuth produced a decrease in CFU per milliliter of < 1 to > 3 log10 units). The activities of these two agents when combined mimicked the activity of the most active drug alone for that growth phase. We conclude that the clinical use of ampicillin combined with bismuth has been more effective than that of either agent used alone because ampicillin targets replicating cells, whereas bismuth targets cells that are not actively replicating.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7695331      PMCID: PMC162486          DOI: 10.1128/AAC.39.1.66

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  On: The who's and when's of therapy for Helicobacter pylori.

Authors:  A Burette; Y Glupczynski
Journal:  Am J Gastroenterol       Date:  1991-07       Impact factor: 10.864

Review 2.  Pathogenesis of peptic ulcer and implications for therapy.

Authors:  A H Soll
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

3.  Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate.

Authors:  T O'Riordan; E Mathai; E Tobin; D McKenna; C Keane; E Sweeney; C O'Morain
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 4.  Drug therapy for Helicobacter pylori infection: problems and pitfalls.

Authors:  Y Glupczynski; A Burette
Journal:  Am J Gastroenterol       Date:  1990-12       Impact factor: 10.864

Review 5.  Campylobacter pylori and its role in peptic ulcer disease.

Authors:  G N Tytgat; E A Rauws
Journal:  Gastroenterol Clin North Am       Date:  1990-03       Impact factor: 3.806

6.  In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.

Authors:  L B Rice; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 7.  Pharmacology of bismuth-containing compounds.

Authors:  J R Lambert
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

8.  Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells.

Authors:  F Megraud; H Lamouliatte; L Boyanova
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 9.  Campylobacter pylori and peptic ulcer disease.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

10.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

View more
  5 in total

1.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.

Authors:  T Alarcón; D Domingo; I Sánchez; F Díaz de Rojas; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

3.  Use of merocyanine 540 for photodynamic inactivation of Staphylococcus aureus planktonic and biofilm cells.

Authors:  Hsiao-Yin Lin; Chin-Tin Chen; Ching-Tsan Huang
Journal:  Appl Environ Microbiol       Date:  2004-11       Impact factor: 4.792

4.  Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of Helicobacter pylori.

Authors:  P E Coudron; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

5.  Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media.

Authors:  P E Coudron; C W Stratton
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.